Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymph node staging in lung cancer using [18F]FDG-PET.

G Halter1, A K Buck, H Schirrmeister

  • 1Department of Thoracic and Vascular Surgery, University of Ulm, Ulm, Germany. gisela.halter@medizin.uni-ulm.de

The Thoracic and Cardiovascular Surgeon
|April 23, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Independent risk factors for COVID-19-associated coagulopathy.

European review for medical and pharmacological sciences·2023
Same author

DNA damage and repair in peripheral blood mononuclear cells after internal ex vivo irradiation of patient blood with <sup>131</sup>I.

European journal of nuclear medicine and molecular imaging·2021
Same author

Correction to: Biokinetics, dosimetry and radiation risk in infants after <sup>99m</sup>Tc-MAG3 scans.

EJNMMI research·2021
Same author

Spatial distribution of pyrogenic carbon in Iberian topsoils estimated by chemometric analysis of infrared spectra.

The Science of the total environment·2021
Same author

Improved cancer detection in Waldeyer's tonsillar ring by <sup>68</sup>Ga-FAPI PET/CT imaging.

European journal of nuclear medicine and molecular imaging·2020
Same author

Pneumologie (Stuttgart, Germany)·2020

Positron emission tomography (PET) using 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG) is a superior, noninvasive method for staging lung cancer lymph nodes compared to computed tomography (CT). FDG-PET accurately identifies mediastinal nodal metastases, aiding treatment decisions.

Area of Science:

  • Oncology
  • Radiology
  • Nuclear Medicine

Background:

  • Mediastinal lymph node staging is crucial for non-small cell lung cancer (NSCLC) treatment planning.
  • Positron emission tomography (PET) utilizes 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG) to detect elevated glucose metabolism in malignant tissues.

Purpose of the Study:

  • To evaluate the efficacy of FDG-PET scanning in staging thoracic lymph nodes in patients with lung cancer.
  • To compare the diagnostic performance of FDG-PET with computed tomography (CT) for N-staging in NSCLC.

Main Methods:

  • A study involving 155 patients with focal pulmonary tumors who underwent both preoperative CT and FDG-PET scans.
  • Analysis of 116 malignant and 39 benign lesions to determine staging accuracy.

Related Experiment Videos

Main Results:

  • FDG-PET demonstrated a sensitivity of 88%, specificity of 91%, and accuracy of 89% for N-staging.
  • CT yielded lower figures: 77% sensitivity, 76% specificity, and 77% accuracy.
  • FDG-PET effectively differentiated between resectable (N1/N2) and unresectable (N3) disease.

Conclusions:

  • FDG-PET is a highly effective, noninvasive tool for staging thoracic lymph nodes in lung cancer patients.
  • FDG-PET significantly outperforms CT in assessing hilar and mediastinal nodal metastases.
  • The findings support FDG-PET's role in guiding operability decisions for NSCLC.